Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

Expert Review of Hematology

Volumn 7, Issue 2, 2014, Pages 255-264

  Gianelli, Umberto ^a   Iurlo, Alessandra ^b   Cattaneo, Daniele ^b   Lambertenghi Deliliers, Giorgio ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c Fondazione Matarelli per Lo Studio e la Cura Delle Malattie Del Sangue   (Italy)

Author keywords

Bone marrow; essential thrombocythemia; megakaryocyte; myelofibrosis; myeloproliferative neoplasms; polycythemia vera; primary myelofibrosis

Indexed keywords

JANUS KINASE 2;

BLEEDING DISORDER; CHROMOSOME STRUCTURE; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; GENE MUTATION; HUMAN; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PATHOLOGIST; PHENOTYPE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POSTESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS; PRIORITY JOURNAL; PRODROMAL SYMPTOM; REVIEW; THROMBOCYTHEMIA; THROMBOSIS; WORLD HEALTH ORGANIZATION;

BONE MARROW; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MEGAKARYOCYTES; MUTATION; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; THROMBOCYTOSIS;

EID: 84896368819     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.876898     Document Type: Review

References (83)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22
2. Tefferi A. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. Leuk Res 2012;36(12): 1481-9
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352(17):1779-90 (Pubitemid 40570926)
4. Tefferi A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 2007;13:366-71
5. Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-83 (Pubitemid 47327415)
6. Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-3 (Pubitemid 47299970)
7. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008;22:1299-307
8. Passamonti F, Rumi E. Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 2009;94:7-10
9. Carobbio A, Finazzi G, Antonioli E, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 2009;37:1016-21
10. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88(6): 507-16 . This review reports the most recent advances in diagnosis and management of polycythemia vera- and essential thrombocythemia (ET) patients, concerning also the high impact of pathologist contribution to a correct diagnosis and the best available therapy for such patients.
11. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477-83
12. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008;22: 756-61 (Pubitemid 351559282)
13. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-9
14. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356(5):459-68 (Pubitemid 46193073)
15. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270
16. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472-6.
17. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112(1):141-9
18. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112(3):844-7
19. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23(5):905-11
20. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360(22):2289-301
21. Abdel-Wahab O, Tefferi A, Levine RL. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am 2012;26(5):1053-64
22. Gelsi-Boyer V, Brecqueville M, Devillier R, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012;5:12
23. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24(7):1302-9
24. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012;26(3):475-80
25. Kvasnicka HM, Bain BJ, Thiele J, et al. Myeloproliferative neoplasm, unclassifiable. In: Campo E, Swerdlow SH, Harris NL et al. editors. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France; 2008. p. 64-5
26. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51
27. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7 (Pubitemid 47281402)
28. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88(2):141-50 . This review reports the most recent advances in diagnosis and management of primary myelofibrosis (PMF) patients, concerning also the high importance of bone marrow morphological examination to make a correct diagnosis and the therapy choice for such patients, although now available drugs are only able to reduce constitutional symptoms, not to eradicate this incurable disorder.
29. Thiele J, Kvasnicka HM, Orazi A, et al. Polycythaemia vera. In: Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES, editors. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France; 2008. p. 40-3
30. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686-9 (Pubitemid 351213460)
31. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol 2005;20:317-28 (Pubitemid 40029008)
32. Thiele J, Kvasnicka HM, Diehl V. Bone marrow features of diagnostic impact in erythrocytosis. Ann Hematol 2005;84:362-7 (Pubitemid 40823349)
33. Thiele J, Kvasnicka HM, Zankovich R, et al. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica 2001;86: 368-74 (Pubitemid 32428495)
34. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-32 (Pubitemid 41323513)
35. Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012;119(10): 2239-41
36. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post- polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-8 (Pubitemid 351250553)
37. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38
38. Thiele J, Kvasnicka HM, Tefferi A, et al. Primary myelofibrosis. In: Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES, editors. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France; 2008. p. 44-7
39. Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008;111:1862-5 (Pubitemid 351451494)
40. Gianelli U, Vener C, Bossi A, et al. The European Consensus on grading of bone marrow fibrosid allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 2012;25: 1193-202
41. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011;117:5857-9 . This review confirms that the most frequent comorbidities in ET patients are represented by arterial and venous thrombotic events; therefore, it is important to identify as earlier as possible these conditions in order to prevent such complications.
42. Thiele J, Kvasnicka HM, Orazi A, et al. Essential thrombocythemia. In: Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES, editors. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France; 2008. p. 48-50
43. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010;85(1):62-9
44. Thiele J. Philadelphia chromosome-negative chronic myeloproliferative disease. Am J Clin Pathol 2009;132:261-80
45. Briere JB. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost 2006;32:208-18
46. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006;130: 2031-8 (Pubitemid 43816970)
47. Smalberg JH, Murad SD, Braakman E, et al. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006;91:1712-13 (Pubitemid 46032973)
48. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708-14 (Pubitemid 46563568)
49. McMahon C, Abu-Elmagd K, Bontempo FA, et al. JAK2 V617F mutation in patients with catastrophic intra-abdominal thrombosis. Am J Clin Pathol 2007;127:736-43
50. Regina S, Herault O, D'Alteroche L, et al. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007;5:859-61 (Pubitemid 46563588)
51. Finazzi G, De Stefano V, Barbui T. Are MPNs vascular diseases? Curr Hematol Malig Rep 2013;8(4):307-16
52. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013;122(13):2176-84
53. Michiels JJ, Commandeur S, Hoogenboom GJ, et al. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Ann Hematol 2007;86: 793-800 (Pubitemid 47497097)
54. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006;44:1528-34 (Pubitemid 44953658)
55. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005;113:213-19 (Pubitemid 40911544)
56. Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the ''early'' prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol 2008;130:336-42
57. Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia Vera (mPV): results of an international study. Am J Hematol 2013. [Epub ahead of print]
58. Barbui T, Thiele J, Carobbio A, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 2012;120(3): 569-71 .
59. Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012;26(4): 716-19
60. Barbui T, Thiele J, Vannucchi AM, et al. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013;27(10): 1953-8
61. Brousseau M, Parot-Schinkel E, Moles MP, et al. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 2010;56:758-67
62. Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 2012;7:e35631
63. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study of 1104 patients. J Clin Oncol 2011;29(23): 3179-84 .
64. Tefferi A, Barbui T. Personalized management of essential thrombocythemia - application of recent evidence to clinical practice. Leukemia 2013;27(8):1617-20
65. Carobbio A, Finazzi G, Thiele J, et al. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. Am J Hematol 2012;87(2):203-4
66. Hussein K, Bock O, Theophile K, et al. JAK2 (V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 2009;37:1186-1193.e7
67. Thiele J, Kvasnicka HM, Zankovich R, et al. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 2000;85: 1126-34
68. Thiele J, Kvasnicka HM. Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol 2005;32:380-94 (Pubitemid 41073751)
69. Florena AM, Tripodo C, Iannitto E, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004;89:911-19
70. Gianelli U, Vener C, Raviele PR, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma 2006;47: 1774-81 (Pubitemid 44649759)
71. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008;93:1645-51
72. Thiele J, Kvasnicka HM, Vardiman JW, et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol 2009;27:e220-1; author reply e222-3
73. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008;111(1):60-70
74. Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009;27(18):2991-9
75. Buhr T, Hebeda K, Kaloutsi V, et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012; 97(3):360-5
76. Gianelli U, Bossi A, Cortinovis I, et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol 2013. [Epub ahead of print]
77. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
78. Tefferi A, Litzow M, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011;365(15):1455-7
79. Harrison C, Vannucchi AM. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol 2012;3(6):341-54
80. Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORTI: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2013; 31(10):1285-92
81. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98
82. Kvasnicka H, Thiele J, Bueso-Ramos CE, et al. Long-term intervention effects on bone marrow morphology in myelofibrosis: patients treated with ruxolitinib and best available therapy. Haematologica 2013; (98 Suppl 2):Abstract S591
83. Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 2013. [Epub ahead of print]